Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingCapital Bluecross genetic testing coverage update …
    Ask Trek AI about this page
    RetiredCapital BluecrossPolicy 2.246

    Genetic Testing for Familial Cutaneous Malignant Melanoma (CDKN2A, CDK4)

    Customize your policy alerts

    Sign up for Capital Bluecross Policy 2.246 alerts

    Get alerted when Policy 2.246 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage stance for germline genetic testing for genes associated with familial cutaneous malignant melanoma (notably CDKN2A and CDK4) for Capital BlueCross members and explains rationale and related guidelines for use.

    Policy Summary
    PayerCapital Bluecross
    PolicyGenetic Testing for Familial Cutaneous Malignant Melanoma (CDKN2A, CDK4)
    Policy CodePolicy 2.246
    Change TypeMajor review — statement changed to investigationalcoding updated
    Effective DateJul 1, 2026
    Last ReviewJun 24, 2025
    Next Review DateN/A
    Key ActionVerify member benefits and prior authorization requirements with Capital BlueCross before ordering genetic testing.
    SourceLink
    POLICY UPDATE CHANGES

    Policy statement changed to investigational (INV).

    Procedure code 81403 was added to the coding table.

    Policy title was updated (formerly 'Germline Genetic Testing for Familial Cutaneous Malignant Melanoma').

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Investigationalcoverage stance
    81403procedure code added
    CDKN2A, CDK4genes named
    06/24/2025most recent review
    FEP PPOproduct note

    Coverage Criteria and Policy Stance

    Investigational / Insufficient Evidence

    Covered when ALL of the following are met

    Investigational stance: Genetic testing for genes associated with familial cutaneous malignant melanoma (familial CMM) is considered investigational due to insufficient evidence of clinical utility and impact on health outcomes.

    Management of patients at high risk focuses on sun protection and surveillance; testing does not currently change management.

    Investigational / Not Covered

    Policy stance following 06/24/2025 major review

    Investigational testing: Germline testing of CDKN2A and CDK4 is designated investigational for the indications described in this policy and is therefore not covered.

    Policy history: 06/24/2025 major review changed the policy statement to investigational and updated the coding table (procedure code 81403 added).

    Genetic testing for genes associated with familial cutaneous malignant melanoma is designated investigational because available evidence does not demonstrate that testing improves health outcomes. The policy finds the evidence insufficient to establish clinical utility: variant interpretation is limited by variable penetrance and residual risk, and current management of affected or high‑risk individuals centers on sun‑protection and vigilant surveillance rather than genotype‑directed interventions.

    As a result, germline testing for familial melanoma genes is not supported for routine coverage under this policy; claims for such testing may be denied as investigational or lacking medical necessity given the absence of demonstrated benefit to patient management or outcomes.

    Per the policy statement, germline testing of CDKN2A and CDK4 is explicitly designated investigational and therefore not covered. The document lists CDKN2A and CDK4 testing as investigational in the context of the policy and states these tests are not covered for the indications described.

    Providers should note that this investigational designation applies to single‑gene testing or multigene panels that include these genes when used for the evaluated indications.

    Clinical utility is lacking because identification of germline variants in familial melanoma genes has not been shown to change management for patients or at‑risk relatives. Current recommended care for affected or high‑risk individuals—sun‑protection measures, regular skin surveillance, and prompt biopsy of suspicious lesions—would not be altered based on the presence of a CDKN2A or CDK4 variant according to the available evidence.

    Limitations affecting clinical validity—such as variable penetrance of reported variants and challenges in variant interpretation—further limit the usefulness of test results to guide different treatment or surveillance strategies.

    The policy statement was changed to investigational (INV) following a major review on 06/24/2025. This material change updated the coverage stance in the current policy window to investigational and updated the coding table (including addition of procedure code 81403).

    Covered Indications

    None supported — Familial indications not covered

    None supported — no clinical indications are covered; familial scenarios are described for context but testing is investigational

    Familial scenarios described: A genetic predisposition to cutaneous malignant melanoma is suspected when: melanoma is diagnosed in multiple family members; multiple primary melanomas occur in one patient; or there is early age of onset. A positive family history is the most significant risk factor (~10% report a first- or second-degree relative).

    Although these familial situations are suggestive of predisposition, the policy concludes testing is investigational due to insufficient evidence of clinical utility.

    Genes named: CDKN2A and CDK4 are specifically named in the policy as genes associated with familial CMM; other low-penetrance loci (e.g., MC1R, variants on 1p22, and various SNPs) are discussed as modifiers but are not the basis for covered indications.

    Testing of these genes is designated investigational in this policy window.

    None explicitly covered — Historical notes (current stance investigational)

    Historical notes are provided for context; current policy designates testing as investigational

    Eligibility Requirements

    No eligibility criteria are specified in this policy window; there are 0 top‑level eligibility nodes defined.

    This policy window contains 0 top‑level eligibility nodes; the policy statement after the 06/24/2025 major review is investigational and no updated eligibility requirements are provided.

    Retained for reference: there are 0 top‑level eligibility nodes in the current policy text; no prior‑testing or family‑history eligibility rules are active in this investigational window.

    Coding and Procedure Codes

    Procedure codes mentionedCPT
    81403Procedure code added to coding table (document notes addition)
    81404Procedure code previously updated to medically necessary in 06/08/2021 history note
    Prior stated threshold (historical)
    Historical thresholdCDKN2A testing was previously described as medically necessary for individuals with 3 or more invasive cutaneous melanomas or for invasive cutaneous melanoma with a first‑degree relative diagnosed with pancreatic cancer (history entry 06/08/2021).
    Status of thresholdThis threshold is a historical note present in policy history; the current policy statement was changed to investigational on 06/24/2025.
    Coding related to historyHistorical update (06/08/2021) also changed coding so that CPT 81404 was noted as medically necessary at that time.

    Provider Actions and Requirements

    Prior Authorization

    Product- or program-specific prior authorization differences

    This policy is applicable only to certain programs and products administered by Capital Blue Cross; program-specific manuals (for example, the FEP PPO) may specify different prior authorization requirements and should be consulted.

    • FEP PPO: refer to the FEP Medical Policy Manual for program-specific rules.
    Prior Authorization

    Confirm coverage and prior authorization with member benefits

    Listed procedure codes do not by themselves indicate coverage; coverage and any prior authorization requirements are determined by the member's benefit terms and are subject to change. Providers must confirm coverage and whether prior authorization is required for the individual member.

    • Procedure codes listed in the policy are not guarantees of coverage.
    • Verify prior authorization requirements per the member's benefit plan.

    Background and Rationale

    Heritable susceptibility to cutaneous malignant melanoma is suspected in families with multiple affected relatives, patients with multiple primary melanomas, or when melanoma presents at an early age. A positive family history is the most important risk factor—about 10% of melanoma cases report a first‑ or second‑degree relative with melanoma. High‑penetrance genes implicated in familial CMM include CDKN2A and CDK4, with additional low‑penetrance loci (e.g., MC1R and various SNPs) that may modify risk.

    Despite identification of these genes, management of individuals at high risk focuses on sun‑exposure reduction, use of sunscreen, and vigilant cutaneous surveillance; genetic test results have not been shown to change these management recommendations in the available evidence.

    Germline genetic testing for genes associated with familial cutaneous malignant melanoma is considered investigational/insufficient evidence to demonstrate clinical benefit and is therefore not supported for coverage under this policy. The policy specifically cites insufficient evidence of clinical utility and the lack of proven impact on health outcomes as the rationale for the investigational designation.

    Providers should verify member benefits and prior authorization requirements, but the policy stance in this window is that such testing is investigational and may be denied on that basis.

    Specifically, germline testing for CDKN2A and CDK4 is listed as investigational and not covered in this policy window. The investigational designation for these genes was affirmed in the 06/24/2025 major review and is reflected in the policy language and coding updates.

    Historical notes in the policy history describe prior medically necessary indications, but those prior indications do not apply in the current investigational policy window.

    Definitions and Gene Notes

    ALLELE(S) definition
    TermALLELE(S)
    DefinitionOne of two or more different genes containing specific inheritable characteristics that occupy corresponding positions (loci) on paired chromosomes.
    ContextUsed in policy definitions to clarify genetic variant terminology when describing familial susceptibility to melanoma.
    PREDISPOSITION definition
    TermPREDISPOSITION
    DefinitionA latent susceptibility to disease which may be activated under certain conditions (e.g., by stress).
    Relevance
    Policy Summary
    PayerCapital Bluecross
    PolicyGenetic Testing for Familial Cutaneous Malignant Melanoma (CDKN2A, CDK4)
    Policy CodePolicy 2.246
    Change TypeMajor review — statement changed to investigationalcoding updated
    Effective DateJul 1, 2026
    Last ReviewJun 24, 2025
    Next Review DateN/A
    Key ActionVerify member benefits and prior authorization requirements with Capital BlueCross before ordering genetic testing.
    SourceLink
    On This Page
    Coverage Criteria and Policy StanceCovered IndicationsEligibility RequirementsCoding and Procedure CodesProvider Actions and RequirementsBackground and RationaleDefinitions and Gene Notes
    Historical prior MN criteria (not current): Prior policy history (06/08/2021) noted CDKN2A testing as medically necessary for individuals with 3 or more invasive cutaneous melanomas or for invasive melanoma with a first-degree relative diagnosed with pancreatic cancer; this is recorded for historical context only and is not operative in the current policy window.

    Policy history updated 06/24/2025 changed the statement to investigational; historical MN language does not apply.

    Current stance: Following the 06/24/2025 major review, no clinical indications are explicitly covered in this policy window; testing is investigational and not medically necessary under the current policy statement.

    Procedure code changes (addition of 81403) and policy title update are noted in history; these do not imply coverage.

    Step Therapy

    High-risk management focuses on surveillance and sun protection, not step therapy

    Management of patients at high risk for cutaneous malignant melanoma focuses on reduction of sun exposure, use of sunscreens, vigilant cutaneous surveillance, and prompt biopsy of suspicious lesions rather than a stepwise genetic testing intervention.

    • Surveillance and sun-protection are the primary management strategies; genetic testing does not currently change management.
    Note

    Investigational designation applies to familial CMM testing

    This policy statement clarifies that testing for familial CMM genes is investigational and not supported by sufficient evidence; providers should follow the investigational designation in coverage determinations.

    • Genetic testing for genes associated with familial cutaneous malignant melanoma is considered investigational.
    Documentation Required

    Document formal genetic counseling when testing is considered

    Formal genetic counseling is recommended when genetic testing for an inherited condition is being considered and should be performed by an individual experienced in genetic medicine and testing methods; documentation of counseling is recommended.

    • Counseling helps patients understand benefits and harms and may reduce inappropriate testing.
    • Counseling should be performed by someone with expertise in genetic medicine and testing methods.
    Documentation Required

    Verify eligibility and medical necessity before ordering

    Providers must verify the member's benefit program, eligibility on the date of service, and that the requested services are medically necessary and appropriate prior to ordering testing.

    • Medical policies are not guarantees of coverage or payment; final claim payment depends on member benefit terms and eligibility.
    Denial Risk

    Investigational status may result in claim denials

    Because germline testing for genes associated with familial CMM is designated investigational, claims for such testing may be denied as investigational/insufficient evidence; testing for CDKN2A and CDK4 is specifically identified as investigational and not covered.

    • Claims for CDKN2A and CDK4 testing may be denied under the policy's investigational/ not covered designation.
    Denial Risk

    CDKN2A and CDK4 testing: investigational — not covered

    Germline testing of CDKN2A and CDK4 is designated investigational and therefore not covered when used for testing these genes; providers should expect denials for claims billed to the listed procedure codes for CDKN2A/CDK4 testing.

    • Policy text: 'Investigational, therefore not covered, when used for testing CDKN2A and CDK4.'
    Documentation Required

    Recommend formal genetic counseling prior to testing

    Formal genetic counseling is recommended in most cases when testing for an inherited condition is considered; providers should arrange and document counseling performed by an experienced individual.

    • Recommend counseling prior to testing to assist with interpretation and risk communication.
    Note

    Use cited guidelines to guide counseling and test selection

    Guidelines cited in the policy (e.g., Melanoma Genetics Consortium, ASCO, NCCN) support the use of genetic counseling and provide selection criteria for testing; providers should consult these references when considering testing.

    • References include Melanoma Genetics Consortium and ASCO/NCCN guideline publications supporting counseling and selection criteria.
    Billing Rule

    Verify coverage and medical necessity; no specific ordering provider required

    Providers must verify coverage and medical necessity with Capital Blue Cross before ordering; the policy does not mandate a specific ordering provider type (e.g., genetics specialist) in this window.

    • No specific ordering provider type is required per the policy text; verify benefits and necessity with the payer.
    Describes inherited risk factors discussed in familial cutaneous malignant melanoma context.
    CDKN2A
    GeneCDKN2A
    RoleA high‑penetrance melanoma susceptibility gene with variable geographic penetrance for melanoma.
    Associated cancersAssociations include increased risk of pancreatic and other cancers in affected families (references cited).
    NotesEpidemiologic and family studies cited in the policy indicate variable penetrance and implications for genetic counseling rather than established changes in clinical management.
    CDK4
    GeneCDK4
    RoleA gene associated with familial melanoma in certain families; less common than CDKN2A but included in hereditary melanoma assessments.
    NotesPhenotypic profiles and associations with modifier variants (e.g., MC1R) have been described in melanoma‑prone families with CDK4 germline mutations.